Title :

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Author(s) :

Marino, Patricia [Auteur]
Touzani, Rajae [Auteur]
Perrier, Lionel [Auteur]
Rouleau, Etienne [Auteur]
Kossi Dede, Sika [Auteur]
Zou, Zhaomin [Auteur]
Charrier, Nathanael [Auteur]
Goardon, Nicolas [Auteur]
Preudhomme, Claude [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172

Durand-Zaleski, Isabelle [Auteur]
Borget, Isabelle [Auteur]
Baffert, Sandrine [Auteur]
Baffert, Sandrine [Auteur]
Barillot, Emmanuel [Auteur]
Bezieau, Stephane [Auteur]
Borget, Isabelle [Auteur]
Coppin, Lucie [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172

Descapentries, Clothilde [Auteur]
Durand-Zaleski, Isabelle [Auteur]
Forget, Sebastien [Auteur]
Frebourd, Thierry [Auteur]
Guardiola, Philippe [Auteur]
Goardon, Nicolas [Auteur]
Houdayer, Claude [Auteur]
Hupe, Philippe [Auteur]
Lacroix, Ludovic [Auteur]
Leclerc, Julie [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172

Lespagnol, Alexandra [Auteur]
Longuemare, Stephanie [Auteur]
Marino, Patricia [Auteur]
Mosser, Jean [Auteur]
Odou, Marie-Francoise [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Perrier, Lionel [Auteur]
Preudhomme, Claude [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172

Revillion, Francoise [Auteur]
Rouleau, Etienne [Auteur]
Sevenet, Nicolas [Auteur]
Soubeyran, Isabelle [Auteur]
Vaur, Dominique [Auteur]

Journal title :

European journal of human genetics

Abbreviated title :

Eur. J. Hum. Genet.

Volume number :

26

Pages :

314-323

Publication date :

2018-03-01

ISSN :

1018-4813

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

It is currently unclear if next-generation sequencing (NGS) technologies can be implemented in the diagnosis setting at an affordable cost. The aim of this study was to measure the total cost of performing NGS in clinical ...
Show more >It is currently unclear if next-generation sequencing (NGS) technologies can be implemented in the diagnosis setting at an affordable cost. The aim of this study was to measure the total cost of performing NGS in clinical practice in France, in both germline and somatic cancer genetics.The study was performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost was estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. In addition, we used a top-down methodology for specific post-sequencing steps including bioinformatics, technical validation, and biological validation. Additional non-specific costs were also included. Costs were detailed per step of the process (from the pre-analytical phase to delivery of results), and per cost driver (consumables, staff, equipment, maintenance, overheads). Sensitivity analyses were performed.The mean total cost of NGS for targeted gene panels was estimated to 607euro (+/-207) in somatic genetics and 550euro (+/-140) in germline oncogenetic analysis. Consumables were the highest cost driver of the sequencing process. The sensitivity analysis showed that a 25% reduction of consumables resulted in a 15% decrease in total NGS cost in somatic genetics, and 13% in germline analysis. Additional costs accounted for 30-32% of the total NGS costs.Beyond cost assessment considerations, the diffusion of NGS technologies will raise questions about their efficiency when compared to more targeted approaches, and their added value in a context of routine diagnosis.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Inflammatory digestive disease : pathophysiology and therapeutic targets developement

Submission date :

2019-03-01T14:17:25Z
2021-05-14T08:21:26Z